NO20050921L - Nye fysiologisk aktive substanser - Google Patents
Nye fysiologisk aktive substanserInfo
- Publication number
- NO20050921L NO20050921L NO20050921A NO20050921A NO20050921L NO 20050921 L NO20050921 L NO 20050921L NO 20050921 A NO20050921 A NO 20050921A NO 20050921 A NO20050921 A NO 20050921A NO 20050921 L NO20050921 L NO 20050921L
- Authority
- NO
- Norway
- Prior art keywords
- active substances
- physiologically active
- new physiologically
- inhibition
- same
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/02—Oxygen as only ring hetero atoms
- C12P17/08—Oxygen as only ring hetero atoms containing a hetero ring of at least seven ring members, e.g. zearalenone, macrolide aglycons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
- C12P17/162—Heterorings having oxygen atoms as the only ring heteroatoms, e.g. Lasalocid
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Forbindelsene representert ved den. etterfølgende generelle formel (I). farmakologisk aksepterbare salter derav, eller hydrater av de samme:. hvori W representerer (1), (2) eller (3); og R,,1, R, R0,2og R' er like eller forskjellige fra hverandre og representerer hver hydrogen osv. På grunn av inhibering av angiogenese og inhibering av fremstillingen av VEGF, særlig ved hypoksi, er forbindelsene (I) anvendbare som midler for faste kreftformer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002224105 | 2002-07-31 | ||
PCT/JP2003/009753 WO2004011661A1 (ja) | 2002-07-31 | 2003-07-31 | 新規生理活性物質 |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20050921L true NO20050921L (no) | 2005-04-28 |
Family
ID=31184996
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20050921A NO20050921L (no) | 2002-07-31 | 2005-02-21 | Nye fysiologisk aktive substanser |
Country Status (13)
Country | Link |
---|---|
US (1) | US7256178B2 (no) |
EP (1) | EP1548121B1 (no) |
JP (1) | JP4328293B2 (no) |
KR (1) | KR101285695B1 (no) |
CN (1) | CN1671856B (no) |
AU (1) | AU2003252445B2 (no) |
BR (1) | BR0313039A (no) |
CA (1) | CA2494536C (no) |
MX (1) | MXPA05001104A (no) |
NO (1) | NO20050921L (no) |
NZ (1) | NZ537830A (no) |
RU (1) | RU2338741C2 (no) |
WO (1) | WO2004011661A1 (no) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI312681B (en) * | 2001-02-01 | 2009-08-01 | Novel physiologically active substance | |
TWI334866B (en) * | 2002-05-29 | 2010-12-21 | Mercian Corp | Novel physiologically active substances |
CN1717493A (zh) * | 2002-11-29 | 2006-01-04 | 美露香株式会社 | 大环内酯化合物的产生方法 |
KR20060110865A (ko) * | 2003-11-27 | 2006-10-25 | 에자이 가부시키가이샤 | 매크로라이드계 화합물의 수산화에 관여하는 dna |
ATE469985T1 (de) * | 2004-02-06 | 2010-06-15 | Eisai R&D Man Co Ltd | Verfahren zur untersuchung der empfindlichkeit einer krebszelle gegenüber einem antikrebsmittel |
JP4599357B2 (ja) * | 2004-07-20 | 2010-12-15 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | プラジエノライドの生合成に関与するポリペプチドをコードするdna |
TW200716744A (en) * | 2005-05-26 | 2007-05-01 | Eisai R&D Man Co Ltd | Genetically modified microorganism and process for production of macrolide compound using the microorganism |
WO2007110705A2 (en) * | 2005-09-28 | 2007-10-04 | Novimmune Sa | Macrolide as inhibitors of mhc class ii |
WO2007043621A1 (ja) | 2005-10-13 | 2007-04-19 | Eisai R & D Management Co., Ltd. | プラジエノライド b及びプラジエノライド dの全合成方法 |
JPWO2008016187A1 (ja) | 2006-08-02 | 2009-12-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | プラジエノライド類のターゲット分子、本ターゲット分子に結合する化合物、及びそのスクリーニング方法 |
AU2008211950A1 (en) * | 2007-01-29 | 2008-08-07 | Eisai R & D Management Co., Ltd. | Solid of macrolide compound, method for production thereof, and pharmaceutical composition comprising the same |
US20080312317A1 (en) * | 2007-04-12 | 2008-12-18 | Eisai R&D Management Co., Ltd. | 12 membered-ring macrolactam derivatives |
GB0821539D0 (en) * | 2008-11-25 | 2008-12-31 | Merlion Pharmaceuticals Pte Ltd | Therapeutic compounds and their use |
RU2707730C2 (ru) | 2014-05-15 | 2019-11-29 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Пиридиновые соединения пладиенолида и способы применения |
EP3344780B1 (en) | 2015-09-01 | 2021-06-23 | Eisai R&D Management Co., Ltd. | Splice variants associated with neomorphic sf3b1 mutants |
KR20180083376A (ko) | 2015-11-18 | 2018-07-20 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 플라디에놀리드 피리딘 화합물의 고체 상태 형태 및 사용 방법 |
SG11201907887SA (en) | 2017-03-15 | 2019-09-27 | Eisai Co Ltd | Spliceosome mutations and uses thereof |
AU2018360559A1 (en) | 2017-10-31 | 2020-05-07 | Eisai R&D Management Co., Ltd. | Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from BCL2 inhibitors, BCL2/BCLxL inhibitors, and BCLxL inhibitors and methods of use |
MX2020010606A (es) | 2018-04-09 | 2021-01-15 | Eisai R&D Man Co Ltd | Compuestos de pladienolida y su uso. |
JOP20200244A1 (ar) | 2018-04-12 | 2020-09-29 | Eisai R&D Man Co Ltd | مشتقات بلاديينوليد كعوامل تستهدف جسيمات الوصل لعلاج السرطان |
WO2019232449A1 (en) * | 2018-06-01 | 2019-12-05 | Eisai R&D Management Co., Ltd. | Splicing modulator antibody-drug conjugates and methods of use |
IL278740B2 (en) | 2018-06-01 | 2024-01-01 | Eisai R&D Man Co Ltd | Methods for using splicing modulators |
CN111973589A (zh) * | 2019-05-21 | 2020-11-24 | 中国科学院近代物理研究所 | pladienolide B在增强宫颈癌细胞辐射敏感性中的应用 |
JP2023553588A (ja) | 2020-11-04 | 2023-12-25 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 骨髄異形成症候群(mds)のバイオマーカー及びその使用方法 |
WO2023131866A1 (en) | 2022-01-05 | 2023-07-13 | Eisai R&D Management Co., Ltd. | Biomarkers for myelodysplastic syndrome (mds) and methods of using the same |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04352783A (ja) * | 1991-05-27 | 1992-12-07 | Taisho Pharmaceut Co Ltd | 12員環マクロライド系化合物 |
SG49853A1 (en) * | 1993-08-16 | 2001-07-24 | Novartis Ag | Novel macrolides and the use thereof |
US6441186B1 (en) * | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
US6380395B1 (en) * | 1998-04-21 | 2002-04-30 | Bristol-Myers Squibb Company | 12, 13-cyclopropane epothilone derivatives |
CA2360952A1 (en) * | 1999-02-11 | 2000-08-17 | Schering Aktiengesellschaft | Epothilon derivatives, method for the production and the use thereof as pharmaceuticals |
TWI312681B (en) * | 2001-02-01 | 2009-08-01 | Novel physiologically active substance | |
TWI233361B (en) * | 2001-04-13 | 2005-06-01 | Gen Hospital Corp | Methods of preventing UVB-induced skin damage |
-
2003
- 2003-07-31 BR BR0313039-8A patent/BR0313039A/pt not_active IP Right Cessation
- 2003-07-31 AU AU2003252445A patent/AU2003252445B2/en not_active Ceased
- 2003-07-31 CA CA2494536A patent/CA2494536C/en not_active Expired - Fee Related
- 2003-07-31 WO PCT/JP2003/009753 patent/WO2004011661A1/ja active Application Filing
- 2003-07-31 KR KR1020057001794A patent/KR101285695B1/ko not_active IP Right Cessation
- 2003-07-31 CN CN038183129A patent/CN1671856B/zh not_active Expired - Fee Related
- 2003-07-31 NZ NZ537830A patent/NZ537830A/en not_active IP Right Cessation
- 2003-07-31 JP JP2004524326A patent/JP4328293B2/ja not_active Expired - Fee Related
- 2003-07-31 EP EP20030771459 patent/EP1548121B1/en not_active Expired - Lifetime
- 2003-07-31 US US10/522,731 patent/US7256178B2/en not_active Expired - Fee Related
- 2003-07-31 RU RU2005105312/04A patent/RU2338741C2/ru not_active IP Right Cessation
- 2003-07-31 MX MXPA05001104A patent/MXPA05001104A/es active IP Right Grant
-
2005
- 2005-02-21 NO NO20050921A patent/NO20050921L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR101285695B1 (ko) | 2013-07-12 |
MXPA05001104A (es) | 2005-09-08 |
US20050245514A1 (en) | 2005-11-03 |
RU2338741C2 (ru) | 2008-11-20 |
EP1548121B1 (en) | 2015-04-29 |
AU2003252445B2 (en) | 2009-09-17 |
CA2494536A1 (en) | 2004-02-05 |
WO2004011661A1 (ja) | 2004-02-05 |
CA2494536C (en) | 2011-10-04 |
JPWO2004011661A1 (ja) | 2005-11-24 |
EP1548121A1 (en) | 2005-06-29 |
RU2005105312A (ru) | 2005-11-20 |
NZ537830A (en) | 2007-12-21 |
US7256178B2 (en) | 2007-08-14 |
CN1671856B (zh) | 2010-05-12 |
JP4328293B2 (ja) | 2009-09-09 |
BR0313039A (pt) | 2005-08-09 |
CN1671856A (zh) | 2005-09-21 |
KR20050044898A (ko) | 2005-05-13 |
AU2003252445A1 (en) | 2004-02-16 |
EP1548121A4 (en) | 2010-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20050921L (no) | Nye fysiologisk aktive substanser | |
NO20072978L (no) | Nye betuinderivater, preparat derav og anvendelse derav | |
EP1541570A4 (en) | NEW PHYSIOLOGICALLY ACTIVE SUBSTANCE | |
NO20060195L (no) | Kinolylamidderivater som CCR-5-antagonister | |
NO20080789L (no) | 1,4-benzotiazepin 1,1-dioksidderivater, fremgangsmate for fremstilling derav, medikamenter inneholdende denne forbindelsen og anvendelse derav som et hypolipid | |
NO20082445L (no) | Neuropeptid-2 reseptor-agonister | |
NO20082338L (no) | Pyrimidinderivater for behandling av avvikende cellevekst | |
EA200701745A1 (ru) | Циклопропанкарбоксамидные производные | |
NO20062021L (no) | Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika | |
NO20055632L (no) | Aromatiske oksyfenyl- og aromatiske sulfanylfenylderivater | |
NO20074657L (no) | Nitrogenholdige aromatiske ringforbindelser | |
NO20061793L (no) | 1,4-disubstituerte isoquinilonderlvater som RAF-kinaseinhibitorer nyttige for behandling av proliferative sykdommer | |
WO2005046589A3 (en) | Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties | |
SE0302760D0 (sv) | New compounds | |
WO2006113552A3 (en) | Cyanoarylamines | |
MX2009004096A (es) | Metabolitos de talarozol. | |
NO20055143L (no) | Doseringsformer innbefattende AG013736 | |
NO20064576L (no) | Pyrimidin-derivater for behandling av avvikende celle vekst | |
TW200640913A (en) | 5-Substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents | |
NO20070089L (no) | DPP-IV inhibitorer | |
NO20082496L (no) | Pyrazinderivater | |
NO20063576L (no) | 1,3-dioksanederivativer og analoge forbindelser for behandling av fedme og diabetes | |
MXPA02003977A (es) | Inhibidores de adhesion de celula mediada por al°2. | |
WO2007017728A3 (en) | Novel heterocyclic compounds | |
EA200600621A1 (ru) | Производные тетрагидронафталина, способ их получения и их применение в качестве противовоспалительных средств |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |